
https://www.science.org/content/blog-post/dealing-data
# Dealing with the Data (Mar 2012)

## 1. SUMMARY  
The article laments the sheer volume of information generated in pre‑clinical drug discovery. A single compound can be linked to hundreds of assay read‑outs, physicochemical properties, spectral data, batch records, and storage locations, resulting in spreadsheets with thousands of columns and millions of rows across a large screening collection. The author notes that big pharma typically rely on proprietary, all‑purpose informatics systems that let users query by structure, assay, or physical property, but such “kitchen‑sink” tools can be cumbersome to learn and may not excel at any one task. The piece asks how smaller companies cope—whether they build in‑house software, adapt commercial packages, or find other affordable ways to organise, visualise, and interrogate their data.

## 2. HISTORY  
**2012‑2016: Early consolidation**  
- Major pharma continued to use legacy LIMS/ELN suites (e.g., Accelrys, ChemAxon, PerkinElmer).  
- Start‑ups and midsize firms began adopting commercial cheminformatics platforms such as **Pipeline Pilot**, **KNIME**, and **Spotfire** for data wrangling and visualisation.  

**2016‑2020: Move to the cloud and SaaS**  
- Cloud‑based laboratory informatics gained traction. Companies like **Benchling**, **Dotmatics**, **Labguru**, and **SciFinder Live** offered integrated ELN/LIMS/compound‑management modules that could be accessed from any browser, reducing the need for on‑premise IT support.  
- The **FAIR data** movement (Findable, Accessible, Interoperable, Reusable) prompted the adoption of standard file formats (SD, JSON‑LD) and metadata schemas, making it easier to share data across organisations and with AI pipelines.  

**2020‑2024: AI‑driven data pipelines**  
- The explosion of machine‑learning models for property prediction (e.g., ADMET, potency) required clean, well‑annotated datasets. Vendors responded with specialised data‑curation tools (e.g., **CDDOCK**, **Schrödinger LiveDesign**, **Molecule.one**) that sit on top of existing LIMS and automatically generate training sets.  
- Open‑source ecosystems (RDKit, Pandas, Jupyter) became common for ad‑hoc analysis, allowing chemists to script custom queries without learning a monolithic GUI.  

**2024‑2026: Hybrid “best‑of‑both‑worlds” platforms**  
- Large pharma now run a **core LIMS** for compliance and a **modular SaaS layer** for analytics (e.g., **DataRobot**, **Snowflake** data warehouses).  
- Smaller companies often rely entirely on SaaS suites (Benchling, Dotmatics) plus open‑source notebooks, achieving the functionality the 2012 article described without building bespoke software.  
- The original pain point—visualising relationships such as microsomal stability vs. log P across species—has been largely solved by built‑in dashboards and drag‑and‑drop charting tools that pull directly from the compound‑management database.  

Overall, the industry has shifted from heavyweight, monolithic in‑house systems to **flexible, cloud‑native, modular platforms** that integrate data capture, visualisation, and AI‑ready pipelines.

## 3. PREDICTIONS  
The article itself did not list explicit forecasts, but it implied several expectations:

| Implied prediction | What actually happened |
|--------------------|------------------------|
| **Large, all‑purpose software will be hard to master and may be replaced by more focused tools.** | True. Many organisations now use a **core LIMS** for compliance and plug‑in analytics tools (KNIME, Spotfire, custom Jupyter notebooks) for specific tasks. |
| **Smaller companies need affordable, possibly home‑built solutions.** | Partially true. Rather than building from scratch, most small‑to‑mid‑size firms adopt **SaaS ELN/LIMS** (Benchling, Dotmatics) that are subscription‑based and require minimal IT overhead. |
| **Visualization of multi‑parameter relationships will become essential.** | Realised. Modern platforms provide **interactive dashboards**, correlation matrices, and 3‑D plots that can be generated with a few clicks. |
| **Data volume will continue to grow, demanding better data‑management strategies.** | Accurate. The rise of high‑throughput phenotypic screens, omics, and AI‑driven modelling has multiplied data points per compound, reinforcing the need for robust data‑governance and FAIR compliance. |

## 4. INTEREST  
**Rating: 6/10** – The piece captures a timeless operational challenge that remains relevant, but it offers no novel scientific insight; its value lies in highlighting a workflow problem that the industry has since addressed with evolving informatics tools.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20120319-dealing-data.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_